Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 31, 2014Phase III data for lenvatinib to be presented at ASCO
Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive...
- May 28, 2014-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting --
Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI® (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with...
- May 22, 2014- Companies Advance Multiple Co-discovery Programs for First-in-class Targets in Oncology -
H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies...
- May 15, 2014Obesity Education Network Provides Tools to Help Physicians Assess and Manage Patients Who are Overweight or Obese
Eisai Inc. today announced the launch of a website that will provide physicians with access to comprehensive clinical information that addresses obesity screening and risk assessment,...
-
May 14, 2014Data underscore breadth of oncology portfolio
Eisai Inc. announced today that 10 abstracts highlighting new study results will be presented during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in...
